Robust cash position of CHF41.7 million providing runway through 2021 Dipraglurant on track to start pivotal registration study in PD-LID by end of year Strengthened team of clinical and preclinical experts Developing broad allosteric modulator pipeline addressing multiple CNS indications Geneva, Switzerland, April 30, 2019 – Addex Therapeutics (SIX: […]
